RecruitingPhase 3Drug trialA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic MigraineTo find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.